Group 1 - OpenAI has made a controversial investment by leading a $250 million seed round in Merge Labs, valuing the company at $850 million, which focuses on non-invasive brain-computer interface technology [3] - Merge Labs aims to integrate biological intelligence with AI, contrasting with Neuralink's invasive surgical approach, and is positioned to enhance human capabilities [3][4] - The investment intensifies competition in the brain-computer interface sector, with Neuralink having a $9 billion valuation and focusing on medical applications, while Merge Labs adopts a Silicon Valley-style vision of "superhuman" capabilities [3] Group 2 - The collaboration between OpenAI and Merge Labs creates a closed-loop business model, where Merge Labs can leverage OpenAI's foundational models and AI tools to accelerate development, potentially making their brain-computer interface products a natural entry point for OpenAI's software [3] - OpenAI's investment is expected to increase the valuation of Merge Labs, aligning the interests of Sam Altman, the CEO of OpenAI, with those of the startup [3]

记者丨陶力 倪雨晴 彭新 孔海丽 董静怡 骆轶琪 编辑丨骆一帆 科技的迭代速度，正愈发超越人们想象。 2025年，人工智能、量子计算、聚变能源、航天工程等关键领域，均迎来突破性进展，中国 与美国在核心赛道的引领与竞争，推动全球科技格局发生深刻变革。从开源AI模型打破算力 垄断到"人造太阳"刷新能源探索纪录，从量子计算逐步突破到商业航天技术成熟，一系列重 大科技事件不仅重塑了产业生态，也改写了技术发展的底层逻辑。 随着技术积累的持续深化与应用场景的不断拓展， 2026年成为科技从"实验室走向产业化"的 关键一年 ，AI与物理世界的深度融合、脑机接口探索商业化、低空经济的规模化发展等趋 势，将进一步推动科技与民生、产业的深度绑定，开启新一轮全球科技革命与产业变革。 21世纪经济报道科技团队在采访行业专家和资深从业人员的基础上，经过深入讨论和研究， 系统梳理出了2025年全球重大科技事件，观察和透视2026年行业发展新趋势，力图呈现科技 浪潮下的产业变革与未来图景。 2 0 2 5年全球科技重大事件回顾 1.DeepSeek引领全球开源AI模型 2025年春节期间，DeepSeek火爆出圈，迅速在全球应用市场霸榜， ...

Group 1 - Merge Labs has officially emerged from stealth mode, announcing a significant seed funding round of $250 million, with a valuation of $850 million, primarily funded by OpenAI [2] - The company aims to connect biological intelligence with artificial intelligence, focusing on non-invasive technologies to restore human capabilities and expand imagination [2] - Merge Labs differentiates itself from Neuralink by pursuing a non-invasive approach, utilizing "molecules rather than electrodes" to connect neurons and employing modalities like ultrasound for information transmission [2] Group 2 - The founding team of Merge Labs includes prominent figures such as Sam Altman, Alex Blania, and Sandro Herbig, along with researchers from Forest Neurotech and Caltech [3] - Sam Altman has previously predicted that human-machine fusion will be essential for survival in the face of potential competition from "superintelligent AI" between 2025 and 2075 [3] - Through Merge Labs, the goal is to bridge the gap between biological and digital intelligence, despite acknowledging that the process may become increasingly "strange" [3]

This is Alex Connley using his Neuralink to control this robot arm by only using his thoughts. He's the first person in the world to participate in Neuralink's Convoy study, a human trial that allows a paralyzed individual to control an assisted robotic arm telepathically. He is also the second person to ever get a Neuralink implant at all. The Neuralink reads his brain signals and then determines exactly where he wants to move his arm. He is one of the brave pioneers of this historic technology and in this ...

文 | 针探局，作者 | 曾可 脑机的伦理问题才是关键。 脑机接口，自踏入2026后，突兀的成为资本市场的新宠。 在部分证券软件统计的概念个股中，"人脑工程"已经有近50家相关企业，分别是涉及脑机安装的医疗器 材类公司、可能涉及脑机制造的消费电子类公司，甚至包括脑机内容提供商、一些软件和游戏公司。 更让人无语的是，连八字都没一撇的事儿，2026年九个交易日内整个板块已经实现超20%的涨幅。总市 值已经突破万亿人民币。 这和马斯克旧事重提有关——最近在一次访谈里，他直白地抛出了个想法：想改写人类的底层代码。他 甚至提出了一个惊人观点：人类有望实现"半永生"，只要能"改写"生命里的既定程序，就能活得更久。 在马斯克的逻辑里，这个"半永生"蓝图分两步走： 第一步靠Neuralink的脑机接口完成"意识捕捉"——往大脑里植入高密度电极阵列，采集神经元信号，最 终生成包含记忆、思维模式的"心智快照"，也就是传统意义上的灵魂。 第二步靠Optimus人形机器人当"意识载体"——让数字化的意识、也就是灵魂有个物理依托，从而实 现"意识转移"。 按照这个思路，等人类身体衰老到极限，就能通过"机械飞升"的方式，让意识以另一种形 ...

Core Insights - Neuralink's brain-computer interface (BCI) devices are set for mass production in 2024, with 13 patients already implanted, enabling them to control devices using their thoughts [1][5] - The global BCI market is projected to reach $400 billion, indicating explosive growth in this sector [2] - Various companies are competing in the BCI space, with different approaches to technology, safety, and performance [2][8] Group 1: BCI Technology Overview - BCI establishes a direct communication channel between the brain and external devices, bypassing traditional neural pathways [2][3] - The BCI process involves four steps: signal acquisition, signal decoding, outputting commands, and feedback [5][6] - There are three main technological routes for BCI: non-invasive, semi-invasive, and invasive, each with its own trade-offs in safety and performance [8][10] Group 2: Non-Invasive and Invasive Approaches - Non-invasive BCIs are safe but have weak signals, making them suitable for consumer applications [10][12] - Semi-invasive BCIs require surgery but offer better signal quality than non-invasive options [16][19] - Invasive BCIs provide high signal strength and precision but come with significant risks, including potential immune responses and long-term degradation of electrodes [19][21] Group 3: Material Innovations - New flexible materials are being developed to reduce damage to brain tissue during electrode implantation [22][26] - The focus is on creating soft, durable materials that can withstand the brain's environment while maintaining high performance [26][29] Group 4: AI's Role in BCI - AI is crucial for processing the vast amounts of data generated by BCIs, enabling real-time translation of brain signals into actions [33][35] - AI enhances the decoding of complex neural signals, making it possible for users to control devices with their thoughts [39][40] - The integration of AI is essential for both reading and writing brain signals, facilitating advanced neural modulation [40][42] Group 5: Key Players in the BCI Market - Neuralink, founded by Elon Musk, aims to create a comprehensive BCI system with high channel density and wireless capabilities [43][45] - Synchron offers a less invasive approach by implanting devices through blood vessels, focusing on practical applications for patients [69][71] - Paradromics targets high-performance BCIs with the ability to record a vast number of neural signals simultaneously [77][79] - Blackrock Neurotech is a long-established player known for its reliable Utah Array technology, widely used in BCI research [82][84] Group 6: Future Prospects and Challenges - Neuralink plans to expand its technology to enhance human capabilities, including speech and vision restoration [63][66] - The BCI industry faces ethical challenges regarding privacy, autonomy, and the implications of enhanced human capabilities [96] - The competition among BCI companies is intensifying, with various strategies being employed to capture market share and advance technology [96]

Group 1 - The construction of a "super factory" by Brain Tiger Technology in Jiangxi marks a significant transition from laboratory research to large-scale production in the brain-computer interface (BCI) sector, aiming for stable supply of tens of thousands of units [1][6] - The factory will produce China's first and the world's second fully implanted, fully wireless, and fully functional BCI system, highlighting the growing market potential across healthcare, consumer electronics, and military applications [1][6] - Global developments include Neuralink's announcement to start large-scale production of BCI devices by 2026, indicating a shift from clinical validation to industrialization [1][6] Group 2 - The Chinese government is actively promoting the BCI industry, with a policy document aiming for breakthroughs in key technologies by 2027 and a robust industry system by 2030 [2][7] - The "14th Five-Year Plan" identifies BCI as a future industry requiring strategic development, with various regions setting clear goals for BCI technology and product applications [2][7] - Successful surgeries have been performed on high-level paraplegics using BCI technology, enabling patients to control devices and participate in rehabilitation and employment activities [2][7] Group 3 - The BCI sector has attracted significant investment, with the A-share market showing a cumulative increase of over 20% since 2026, and several stocks rising more than 50% [3][8] - As of January 13, 2023, the financing balance for 26 BCI-related stocks reached nearly 25.5 billion yuan, a 15% increase from the previous year, with many stocks seeing substantial increases in their financing [3][8] - Notable companies include Meihua Medical, with a financing balance of 470 million yuan and a 255% increase, and Innovation Medical, with a balance of 744 million yuan and a 105% increase [3][8][9]

Group 1 - The core point of the article highlights the significant advancements in the brain-computer interface (BCI) industry, particularly with the construction of Brain Tiger Technology's "super factory" in Jiangxi, which marks a transition from laboratory research to large-scale production of BCI systems [3] - The factory aims to produce the first domestically developed and the world's second fully implanted, wireless, and fully functional BCI system, targeting stable supply of tens of thousands of units [3] - The BCI technology shows immense potential across various sectors, including healthcare, consumer electronics, and military aerospace, with significant developments occurring globally [3] Group 2 - The Chinese government is actively promoting the BCI industry, with a policy document issued in July 2025 outlining goals for technological breakthroughs and the establishment of a robust industry framework by 2030 [4] - The market for BCIs is projected to grow significantly, with global market size expected to reach approximately $2.62 billion in 2024 and $12.4 billion by 2034, while China's market is anticipated to grow from 3.2 billion yuan in 2024 to 5.58 billion yuan by 2027, reflecting a compound annual growth rate of about 20% [4] Group 3 - The BCI sector has attracted substantial investment, with the A-share market seeing a cumulative increase of over 20% in the BCI theme index since 2026, and several stocks experiencing gains exceeding 50% [5] - As of January 13, 2023, 19 out of 26 BCI concept stocks were eligible for margin trading, with a total financing balance of nearly 25.5 billion yuan, an increase of over 15% compared to the end of the previous year [5] - Notable companies such as Meihua Medical and Innovation Medical have seen significant increases in their financing balances, indicating strong investor interest and strategic partnerships in the BCI field [5][6]

Core Viewpoint - The company, Meihao Medical, is a strategic partner and core supplier for artificial cochlear implants, which are crucial for brain-machine interface applications, and is exploring technical collaborations with innovative brain-machine interface clients [1] Group 1: Business Collaboration - Meihao Medical has a nearly 15-year deep collaboration with clients in the research and production transformation of artificial cochlear components [1] - The company is involved in the development of invasive brain-machine interface products, focusing on material selection, biocompatibility, production processes, and quality control, which are closely related to artificial cochlear technology [1] Group 2: Revenue and Market Position - Currently, the revenue generated from the company's brain-machine interface business is relatively small [1]

Core Viewpoint - Neuralink, a brain-computer interface company owned by Elon Musk, plans to begin large-scale production of brain-computer interface devices in 2026 and is completing a new round of financing. The company is exploring potential business collaborations with other firms in the industry [1]. Group 1: Company Collaboration - Meihua Medical (301363.SZ) confirmed on an investor interaction platform that it is a strategic partner and core supplier for artificial cochlear implants, which are a significant application direction for brain-computer interfaces [1]. - The company has nearly 15 years of deep collaboration with clients in the research and development and production transformation of artificial cochlear components [1]. - The invasive brain-computer interface products share key technological aspects with artificial cochlear implants, including material selection, biocompatibility requirements, production processes, and quality system control [1]. Group 2: Business Development - The company is actively engaging in process exploration and technical cooperation with innovative brain-computer interface clients to assist them in efficiently commercializing their products from laboratory research to mass production [1]. - Currently, the revenue generated from the company's brain-computer interface business is relatively small [1].